Lenalidomide.

DRUG2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, PETHEMA Foundation

Conditions

Multiple MyelomaNewly Diagnosed Multiple Myeloma

Phase 1

BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma

Active, not recruitingNCT03070327

Memorial Sloan Kettering Cancer CenterMultiple Myeloma

Start: 2017-02-27End: 2027-02-01Updated: 2026-03-04

Phase 3

Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

Active, not recruitingNCT03742297

PETHEMA FoundationNewly Diagnosed Multiple Myeloma

Start: 2018-10-22End: 2031-01-31Updated: 2022-09-14

Related Papers

Validation of the High-Risk Consensus Genomic Staging System in Newly Diagnosed Multiple Myeloma

Blood2025-11-03

Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.

2025-08-011 citations

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Blood2022-09-2149 citations

Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies

Blood Advances2020-08-11252 citations

Hematopoietic Recovery Following Chimeric Antigen Receptor T Cell (CAR T) Therapy in Hematological Malignancies

Biology of Blood and Marrow Transplantation2020-01-231 citations

Hematological Count Recovery in Patients Undergoing Treatment with Chimeric Antigen Receptor T Cells (CAR T)

Blood2019-11-13

Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma

Journal of Hematology & Oncology2018-10-2261 citations